Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein by Byun, Jung S. et al.
Byun et al. Cell Death and Disease          (2019) 10:689 
https://doi.org/10.1038/s41419-019-1892-7 Cell Death & Disease
ART ICLE Open Ac ce s s
Epigenetic re-wiring of breast cancer by
pharmacological targeting of C-terminal binding
protein
Jung S. Byun1, Samson Park2, Dae Ik Yi2, Jee-Hye Shin3, Sara Gil Hernandez2, Stephen M. Hewitt4, Marc C. Nicklaus5,
Megan L. Peach6, Laura Guasch5, Binwu Tang3, Lalage M. Wakefield3, Tingfen Yan7, Ambar Caban1, Alana Jones 1,
Mohamed Kabbout1, Nasreen Vohra8, Anna María Nápoles1, Sandeep Singhal9, Ryan Yancey9, Adriana De Siervi10 and
Kevin Gardner1,9
Abstract
The C-terminal binding protein (CtBP) is an NADH-dependent dimeric family of nuclear proteins that scaffold
interactions between transcriptional regulators and chromatin-modifying complexes. Its association with poor survival
in several cancers implicates CtBP as a promising target for pharmacological intervention. We employed computer-
assisted drug design to search for CtBP inhibitors, using quantitative structure-activity relationship (QSAR) modeling
and docking. Functional screening of these drugs identified 4 compounds with low toxicity and high water solubility.
Micro molar concentrations of these CtBP inhibitors produces significant de-repression of epigenetically silenced pro-
epithelial genes, preferentially in the triple-negative breast cancer cell line MDA-MB-231. This epigenetic
reprogramming occurs through eviction of CtBP from gene promoters; disrupted recruitment of chromatin-modifying
protein complexes containing LSD1, and HDAC1; and re-wiring of activating histone marks at targeted genes. In
functional assays, CtBP inhibition disrupts CtBP dimerization, decreases cell migration, abolishes cellular invasion, and
improves DNA repair. Combinatorial use of CtBP inhibitors with the LSD1 inhibitor pargyline has synergistic influence.
Finally, integrated correlation of gene expression in breast cancer patients with nuclear levels of CtBP1 and LSD1,
reveals new potential therapeutic vulnerabilities. These findings implicate a broad role for this class of compounds in
strategies for epigenetically targeted therapeutic intervention.
Introduction
The C-terminal binding protein (CtBP) was first
described as a phosphoprotein that binds specifically to
the C-terminal end of the E1a adenovirus oncogene1–3.
These proteins were later found to represent a dimeric
family of proteins, composed of CtBP1 and CtBP2, that
can homodimerize or heterodimerize in the nucleus to
influence multiple different epigenetic nuclear events by
recruiting a diverse array of chromatin-modifying com-
plexes2,4. Binding partners for CtBP include histone dea-
cetylases, histone methyltransferases, and histone
demethylases in addition to several different classes of
sequence-specific DNA binding proteins and chromatin-
associated complexes2,3. Therefore, in its dimeric form,
CtBP has the broad potential of re-shaping the landscape of
epigenetic regulation throughout the nucleus5,6. CtBP
belongs to a family of NAD-dependent D-2-hydroxy acid
dehydrogenases including E. Coli D-3-phosphoglycerate
dehydrogenase, bacterial D-lactate dehydrogenase (D-
LDH) and D-hydroxyisocaproate dehydrogenase7. Though
the actual substrate for CtBP remains unclear8–10, its ability
to dimerize and form higher order oligomers is positively
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regulated by NADH/NAD+7,11. The ability of CtBP to
bind and undergo redox cycles with NADH/NAD+ and
substrate implicates a substantial role for CtBP in the
regulation of genomic responses to changes in cellular
metabolism9,12.
CtBP levels are elevated in multiple different cancers to
profoundly influence cellular phenotypic plasticity by
promoting pathways linked to epithelial-to-mesenchymal
transition, cell migration, decreased genome stability and
the acquisition of stem cell self-renewal features13–16. The
increasing role of epigenetic regulation in tumor hetero-
geneity, cellular plasticity and the acquisition of drug
resistance17 suggests a significant potential function for
CtBP as a major determinant in the epigenetic control of
cancer. These dramatic properties implicate CtBP as a
promising candidate for targeted disruption by small
molecule inhibitors as a therapeutic approach against
cancer18–23. The first proof of this principle was provided
by the discovery that 2-Keto-4-methylthiobutyrate
(MTOB), an intermediate in methionine metabolism, is
a selective inhibitor of CtBP activity capable of disrupting
tumor growth in murine models10,18. However, MTOB
requires 10mM concentration to be effective and is
therefore considered impractical as a therapeutic agent10.
Recently, the crystallographic structure of the dehy-
drogenase domains of both CtBP2 and CtBP1 in complex
with MTOB and NAD+ has been resolved20. This
advance provided a framework through which more
effective CtBP inhibitors were designed through compu-
tational methods20–22. Using a similar approach, 24
commercially available compounds with potential as CtBP
inhibitors were identified. Four lead compounds were
selected from these candidates based on their solubility,
low cytotoxicity and ability to reverse transcriptional
repression by CtBP. Further characterization of these
compounds indicates that they have potent activity
against CtBP at low micromolar concentrations to induce
significant alterations in epigenetic transcriptional pro-
gramming in breast cancer.
Results
Identification of small molecular inhibitors of CtBP
We exploited the observation that most dehydrogenases
have strict substrate specificities and the recent publica-
tion of the crystallographic structure of MTOB in com-
plex with CtBP20 to conduct virtual screening of the
ChemNavigator iResearch Library from Sigma Aldrich24
to select molecules that showed favorable interactions
with three residues (His315, Glu295, Arg 266) demon-
strated to function as a catalytic triad in the active site of
CtBP8. This computational screen identified 31 com-
pounds of which 24 were commercially available. The
docked structures of four representative compounds are
shown in Fig. 1a and the structures of the 24 compounds
identified are shown in Fig. 1b. These 24 compounds were
then experimentally screened for influence on viability
and proliferation by MTT assay (Fig. 1c) and combined
viability, cytotoxicity and apoptosis assay (Fig. 1d).
CtBP functions as both an activator and repressor of
transcription although most interactions described thus
far are repressive2. The transcriptionally repressive activ-
ity of CtBP is ascribed to its ability to bind and recruit a
variety of chromatin-modifying enzymes that remove
activating chromatin modifications including histone 3
and 4 lysine acetylation and trimethylation of histone 3 at
lysine 42,3. However, the function of CtBP is highly cell-
type specific, in part due to the differential expression of
various chromatin regulatory complexes and the differ-
ential abundance of proteins that destabilize and, there-
fore, downregulate CtBP activity including: APC, HIPK2,
AMPK, and JNK12,3. In breast cancer, over-expression of
CtBP is associated with downregulation of a variety of
pro-epithelial genes in ER+ tumors but has little effect on
the expression of these genes in breast cancer cell types
with more mesenchymal or stromal features14. Down-
regulation or depletion of CtBP by RNAi-mediated gene
depletion results in upregulation of pro-epithelial genes in
the mesenchymal breast cancer cell line MDA-MB-23114.
We applied a functional screen for the loss of CtBP
transcriptional repressive activity by screening the 24
compounds for the ability to upregulate FOXA1 and
OVOL2, two genes that are intimately involved in main-
taining the epithelial phenotype25–28. This functional
screen identified several compounds that substantially
(greater than two-fold) upregulate FOXA1 and/or OVOL2
expression (Fig. 1e). From this screen, 4 compounds
(CI19, CI22, CI23, and CI24) showing both the lowest
cytotoxicity, and upregulated FOXA1 and OVOL2
expression in MDA-MB-231, were selected (Fig. 1e). All
four of these compounds have molecular weights less than
300 Da and are water-soluble (Fig. 1f).
CtBP inhibitors disrupt CtBP dimerization in vivo
CtBP activity is dependent on its ability to form dimers
and higher order oligomers. This property enables CtBP
to recruit chromatin-modifying complexes to specific
chromatin locations and stabilizes CtBP against nuclear
export and degradation2,3. As shown in Fig. 2, assessment
of CtBP1/CtBP2 dimerization by fluorescent resonance
energy transfer (FRET) acceptor photobleaching29 reveals
a significant decrease in the paired CtBP1-YFP/CtBP2-
CFP FRET signal, after incubation with CI19, CI22, CI23
or CI24 (Fig. 2a, b). This is consistent with the observation
that CI19, CI22, CI23, and CI24 are also able to induce the
release of CtBP2 from immuno-precipitated CtBP1
complexes in vitro (Supplementary Fig. 2). Finally, the
dose-response for CI24 suggests the IC50 for CtBP
dimerization lies between 10 and 20 μM (Fig. 2c).
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Disruption of epigenetic control of transcription by CtBP
small-molecule inhibition
These four lead compounds were then screened for
their specific ability to target and de-repress pro-epithelial
genes that are known to be transcriptionally silenced in
the mesenchymal triple negative breast cancer cell line
MDA-MB-23130,31. As shown in Fig. 3a, b, analysis by
CtBP chromatin immunoprecipitation, using an antibody
that recognizes both CtBP1 and CtBP213,14, demonstrates
that treatment of MDA-MB-231 cells with 10 μM of the
CtBP inhibitor results in eviction of CtBP from the pro-
moter regions of the master epithelial regulatory genes
OVOL2, GATA3, FOXA1, and GRHL214, in addition to the
pro-epithelial micro-RNAs, miR200c and miR203. This
Fig. 1 Identification and validation of small molecule CtBP inhibitors by computer-assisted drug design using QSAR-based modeling.
a Representative docked structures of four small molecular inhibitors in the active site of CtBP. Four lead compounds (CI19, CI22, CI23, and CI24) are
shown in green in the CtBP substrate binding site. The NAD+ cofactor is colored in light blue. Hydrogen bonds are indicated with dashed black lines.
b Structures of 24 commercially available predicted inhibitors of CtBP screened based on best QSAR predicted activities and highest docking scores.
c Proliferation and viability screening of MDA-MB-231 cells treated 24 h with 10 μM of the 24 predicted CtBP inhibitors as determined by MTT assay.
d Viability, cytotoxicity, and apoptosis screen of MDA-MB-231 cells treated 24 h with 10 μM of the 24 predicted CtBP inhibitors as assessed by the
ApoTox-Glo™ Triplex Assay. Samples were normalized and subject to hierarchical clustering using a correlation matrix and centroid linkage.
Dendrogram highlighted in red contains the 4 lead compounds with the lowest cytotoxicity and highest de-repression of CtBP target genes. e qRT-
PCR profiling of mRNA abundance of CtBP-repressed genes, FOXA1 and OVOL2, in MDA-MB-231 cells after treatment for 24 h with 10 μM of the
indicated CtBP inhibitors. f Table showing the relative water solubility of the 4 lead compounds based on AlogP (octanol/water partition coefficient)
and QPlogS (predicted aqueous solubility). All experiments represent the average and standard error of at least two biological replicates. The error
bars represent the s.d. of the mean from at least two independent experiments.*Indicates p-values < 0.05 and **indicated p-value < 0.001
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CtBP promoter eviction is associated with significant
upregulation of the RNAs for OVOL2, GATA3, FOXA1,
GRHL2, miRNA miR200c, miR203, and the well-known
CtBP-repressed genes, E-Cadherin and BRCA113,32 (Fig. 3c).
This gene reactivation in MDA-MB-231 is reflected by an
increased level of protein expression (Fig. 3d, bottom).
Notably, as shown in Fig. 3d, this drug-induced eviction
occurs in the absence of appreciable loss or shift in neither
total CtBP1 nor CtBP2 protein levels from the cytosolic and
nuclear compartments (Fig. 3d, top). The relatively modest
increase in both OVOL2 and FOXA1 protein levels likely
reflects differential influences of both post-transcriptional
(RNA stability and decay) and post-translational steps in
OVOL2 and FOXA1 regulation.
A survey comparing the CtBP inhibitor-induced tran-
scriptional de-repression of the pro-epithelial genes in cell
lines characterized by higher levels of epithelial differ-
entiation, including the estrogen-receptor positive MCF-7
cell line, and the non-transformed mammary epithelial
cell line MCF-10A is shown in Fig. 4. For each compound,
this survey demonstrates similar trends but lower levels of
transcriptional reactivation by the CtBP inhibitor com-
pounds in both MCF-7 and MCF-10A (Fig. 4). These
findings indicate a cell-specific dose-sensitivity to CtBP
inhibition.
CtBP inhibitors disrupt recruitment of histone modification
machinery
Multiple studies have shown that CtBP ferries different
chromatin-modifying complexes to chromatin depending
on the promoter or enhancer context13–15,33. These
recruited assemblies then affect changes in the local epi-
genetic marks specific to the composition of the assem-
bled complexes. Two classes of chromatin modifiers that
have been commonly shown to associate with CtBP are
the histone deacetylases HDAC1 and HDAC2 and the
H3K4Me2/1 demethylase, LSD16,34,35. LSD1 (KDM1A) is
a monoamine oxidase that catalyzes the removal of
H3K4Me2 and K3K4Me1 activation marks by demethy-
lation, thus disrupting the ultimate accumulation of the
active H3K4Me3 modification to play a pivotal role in
modulating epithelial-to-mesenchymal transition36. By
ChIP analysis, the addition of the CtBP inhibitors results
in significant eviction of HDAC1 from the OVOL2,
FOXA1, GRHL2, GATA3, miRNA 200c, and miRNA 203
promoters (Fig. 5a) with a similar pattern for LSD1 ChIP
(Fig. 5b). Accordingly, loss of LSD1 and HDAC1 from
these respective promoter regions is associated with sig-
nificant increases in both histone 4 acetylation and the
deposition of H3K4Me3 marks at the promoter regions of
GATA3, GRHL2, FOXA1, OVOL2, miRNA 200c, and
miRNA 203 (Fig. 5c).
CtBP inhibition increases DNA repair and blocks cell
migration and invasion
One of the most characterized influences of CtBP on
cellular phenotype is its role in promoting cellular
migration, a key gain of function in cells undergoing
epithelial-to-mesenchymal transition and a central feature
during tumor metastasis32. As shown in Fig. 6a, RNAi-
mediated depletion of CtBP in MDA-MB-231 leads to a
demonstrable decrease in cell migration, compared to
empty vector control (pGIPz) as measured by a wound
closure assay (right). Incubation of wild type MDA-MB-
231 cells with 10 μM CtBP inhibitors decreases cell
migration throughout the time course of the wound clo-
sure assay with greater influences caused by compounds
CI23 and CI24 (Fig. 6a, right). Similarly, at 10 micromolar
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abundance in MDA-MB-231 cells treated 24 h with 10 μM CtBP inhibitors as indicated. d (Top), immuno-blot profiling of CtBP1 and CtBP2 in nuclear
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concentration, all 4 compounds inhibit both invasion and
migration as demonstrated in Matrigel® invasion chamber
assays (Fig. 6b).
CtBP forms complexes at the promoters of numerous
genes involved in DNA repair, including the BRCA1
promoter and numerous members of the Fanconi Anemia
complementation group5,13,14,23. Prior studies have shown
that depletion of CtBP results in increased DNA repair
detectable in both comet and gamma H2A.X foci for-
mation assays14,37. In gamma H2A.X-labeled DNA repair
foci assays, the addition of either CtBP inhibitors CI19,
CI22, CI23, or CI24 at 10 micromolar concentrations
causes increases in DNA repair as demonstrated by the
significant decrease in remaining repair foci 24 h follow-
ing exposure to ionizing radiation (Fig. 6c, d). Notably,
the increase is comparable and, in some cases, exceeds
that caused by RNAi-mediated CtBP gene depletion
(Fig. 6d)14.
Synergistic pharmacological targeting of LSD1 in
combination with CtBP
LSD1 was one of the first chromatin regulatory com-
plexes to be found in association with CtBP6. Several
recent studies have suggested the value of targeting LSD1
in therapeutic strategies to epigenetically treat breast
cancer alone or in combination with other epigenetic
disruptors38–43. The LSD1 inhibitor, pargyline has been
used in the past alone or in combination with HDAC
inhibitors to induce growth inhibition and apoptosis in
TNBC cells39,42,44. Notably, the combination of these
drugs were found to be more than additive for TNBCs
and additive or competitive in non-TNBC cell lines39.
Because CtBP is a well-characterized HDAC associated
component of chromatin-modifying complexes, we
explored the effectiveness of combining LSD1 inhibition
with CtBP inhibition as a surrogate for HDAC disruption.
As shown in Fig. 7a, while the addition of pargyline alone
minimally reactivates pro-epithelial gene expression in
MDA-MB-231, its combination with CtBP inhibitors
show additive to synergistic responses in the de-
repression of pro-epithelial genes, particularly with
respect to CI24. A comparison of the functional influ-
ences of pargyline and CI24 alone and in combination on
cellular migration was profiled over time (24 h) using the
IncuCyte ZOOM™ assay. As shown in Fig. 7b, while both
CI24 and pargyline repress migration in this assay, their
combination produces greater than additive effects.
Logistic regression reveals that the combination of CI24
and pargyline have their greatest influence over time in
the migration assay (Fig. 7c, d). Using the T-statistic, the
combination of Pargyline and CI24 have significantly
greater than additive influence on TNBC cell migration:
(p-value= 5.27 E−08) compared to CI24 (p-value=
0.249) or Pargyline (p-value= 0.0002) alone.
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biological replicates. P-values are calculated from the Student’s T-Test relative to the vehicle control. *Indicates P < 0.05 and **indicates P < 0.01
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Fig. 5 (See legend on next page.)
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Nuclear CtBP and LSD1 associated pathways in breast
cancer patients
Previous studies have shown that patient breast cancer
samples that co-express high levels of LSD1 and histone
deacetylases (SIRT1, HDAC2) have decreased survival45.
To evaluate the possible significance of high nuclear levels
of CtBP and LSD1 in breast cancer survival, we utilized a
unique resource of patient samples in which nuclear,
CtBP1, CtBP2, and LSD1 have been quantitatively deter-
mined and compared to paired gene expression data
based on RNA-seq analysis (Material and methods, also
see Supplementary Fig. 3). Using this available data, 126
breast cancer patients were quantitively stratified
according to CtBP1, CtBP2, and LSD1 nuclear expression
into low, medium and high terciles of expression (see
Materials and methods). Notably, within this cohort, the
level of CtBP1 or CtBP2 did not differ greatly in patients
between breast cancer subtypes or estrogen receptor
status. In fact, slightly higher levels were demonstrated in
estrogen-receptor-positive subtypes as opposed to estro-
gen receptor-negative subtypes (Supplementary Fig. 3).
These categories were then used to group patients,
according to their CtBP1, CtBP2 and LSD1 nuclear
expression, in to three categories: (I) CtBP1/LSD1= Low:
(see figure on previous page)
Fig. 5 Treatment with CtBP inhibitors is associated with LSD1 and HDAC1 eviction and increased deposition of activating chromatin marks
at the promoter-proximal regions of pro-epithelial genes in MDA-MB-231. a qChIP profiles in MDA-MB-231 cells of HDAC1 eviction from the
GRHL2, FOXA1, OVOL2, GATA3, miRNA 200c, and miRNA 203 proximal promoter regions following 24-h incubation with vehicle or 10 μM CtBP
inhibitors. b qChIP profiles of LSD1 eviction from the GRHL2, FOXA1, OVOL2, GATA3, miRNA 200c, and miRNA 203 proximal promoter regions
following 24-h incubation with vehicle or 10 μM CtBP inhibitors. c qChIP profiles of changes in histone 4 (K5,8,12,16) pan-acetylation (left) and histone
3 lysine 4 trimethylation (right) at the promoters and upstream regions of GATA3, GRHL2, FOXA1, OVOL2, miRNA 203, and miRNA 200c following 24-h
incubation of MDA-MB-231 cells with 10 μM CtBP inhibitors. The error bars represent the s.d. of the mean from at least two independent experiments.
P-values are calculated from the Student’s T-Test relative to the vehicle control. *Indicates P < 0.05 and **indicates P < 0.01
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Fig. 6 Pharmacologic inhibition of CtBP decreases cellular invasion and migration and increases DNA repair in MDA-MB-231. a (Left),
Relative migration at 9 and 12 h of MDA-MB-231 cells transduced with doxycycline-inducible (96 h) lentiviral vector expressing a shRNA that targets
both CtBP1 and CtBP214. (Right), Wound closure assay of MDA-MB-231 cells pre-treated 24 h with 10 μM CtBP inhibitors. The inset shows relative
migration at 6 h of incubation. (*indicates P < 0.05). b Fluorescent images (left) and graph (right) of invading and migrating MDA-MB-231 cells on
DAPI stained membranes following 24-h treatment of cells with vehicle or 10 μM CtBP inhibitors during invasion and migration in Corning® Biocoat™
Matrigel® Invasion Chambers. All experiments represent the average and standard error of at least two biological replicates with each experiment
performed at least twice. The error bars represent the s.d. of the mean from at least two independent experiments. P-values are calculated from the
Student’s T-Test relative to the vehicle control. *Indicates P < 0.05 and **indicates P < 0.01. c (Top) Phospho-gamma H2AX foci profile of cells
following ionizing radiation (5 Gy) and recovery at 0, 12 and 24 h. d Relative rate of DNA repair is expressed as total percent of nuclei containing two
or more phospho-gamma H2AX foci per high power field. The error bars represent the s.d. of the mean from at least two independent experiments.
P-values are calculated from the Students T-Test relative to the vehicle control. *Indicates P < 0.05 and **indicates P < 0.01
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Low= low; (II) CtBP1:LSD1, medium:medium=medium;
and (III) CtBP1/LSD1= high:high= high (Fig. 8a). The gene
expression of the patients in these three categories were
then assessed by analysis of variance (ANOVA) (Fig. 8a) to
identify genes that were differentially expressed between
the three groups. Examples of differentially expressed
genes are shown by boxplot in Fig. 8a. Notably, many
genes linked to chromatin modification and cell signaling
are enriched in the genes differentially expressed in these
categories (Fig. 8a, and Supplementary Tables 1–4). Simi-
larly, genes that are differentially expressed based on the
stratification of CtBP1/CtBP2 or LSD1, respectively, were
identified (Supplementary Table 1). A Venn diagram of
the genes common to all three stratifications is shown in
Fig. 8b and demonstrates very little overlap. Moreover, the
gene pathways enriched in the genes differentially
expressed by ANOVA of the three stratifications show
significant differences (Fig. 8c–e). CtBP1/LSD1 differen-
tially expressed genes show significant enrichment for
growth factor signaling, CtBP1/CtBP2 differential
expressed genes are enriched for immune response genes
including immune checkpoint regulators (Fig. 8d), and
LSD1 only differentially expressed genes are enriched
with genes associated with regulation of the extracellular
matrix (Fig. 8e). Unique genes identified by ANOVA
profiling of differentially expressed genes across 5 cate-
gories of CtBP1:LSD1 combinations (including CtBP1:
LSD1= Low/High and CtBP1:LSD1=High/Low) was not
additionally informative (Fig. S4 and Supplementary
Tables 1 and 5).
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Fig. 7 Pharmacologic inhibition of CtBP potentiates LSD1 inhibition to depress pro-epithelial gene expression and decrease breast cancer
cell migration. a Relative expression of the pro-epithelial genes OVOL2, GATA3, FOXA1, and GRHL2 in MDA-MB-231 cells treated with vehicle alone,
2.5 mM pargyline alone, CI24 inhibitor alone or in combination with 2.5 mM pargyline and 10 μM CtBP inhibitors. The error bars represent the s.d. of
the mean derived from at least two independent experiments. P-values are calculated from the Student’s T-Test relative to the vehicle control.
*Indicates P < 0.05 and **indicates P < 0.01. b IncuCyte ZOOM™ assay of MDA-MB-231 cell migration in cells treated with either vehicle, 10 μM CI24
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Fig. 8 Inferred gene targets and pathway vulnerabilities associated with combined nuclear enrichment of CtBP1 and LSD1 in breast
cancer patients. a Boxplot displays representative of genes that showed significant differential expression by ANOVA analysis (p-value < 0.05) across
the three breast cancer patient categories stratified by low, medium, and high nuclear co-expression of CtBP1 and LSD1 using a quantitative
immune-histochemical analysis of nuclear staining for CtBP1, and LSD1 based on analysis of the RNA-seq profiles from each patient in each class (see
materials and methods). ANOVA test was applied to identify which genes differed significantly across the three categories. (p-values for paired
categories are also shown). b Venn diagram showing the overlap between genes there were significantly differentially expressed in the categories:
CtBP1/LSD1, CtBP1/CtBP2, and LSD1. c Pathway analysis showing significantly enriched pathway genes that are differentially expressed in association
with CtBP1/LSD1 nuclear expression. d Pathway analysis showing significantly enriched pathway genes that are differentially expressed in association
with CtBP1/CtBP2 nuclear expression. e Pathway analysis showing significantly enriched pathway genes that are differentially expressed in
association with LSD1 nuclear expression alone
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Discussion
In summary, using computer-assisted drug design to
screen for possible inhibitors of CtBP function, we have
identified four lead compounds that, through disruption
of CtBP dimerization, reactivate CtBP-repressed genes.
The mechanisms underlying this inhibitory activity are
associated with the ability of this class of compounds to
disrupt the CtBP-mediated recruitment of multiple dif-
ferent chromatin-modifying complexes to targeted genes.
These include the histone deacetylase, HDAC1; and the
histone demethylase, LSD1. These findings not only
implicate an important application of these compounds in
strategies for therapeutic intervention but also demon-
strate their utility as investigative tools to define epige-
netic gene regulatory pathways and mechanisms linked to
CtBP. The application of these compounds as investiga-
tive tools also provides a proof of principle for the com-
binatorial use of CtBP inhibitors with other epigenetically
targeted compounds or therapeutic strategies. The com-
bined use of LSD1 and CtBP inhibitors offers a new
concept in this therapeutic approach.
The current rapid expansion of novel strategies to target
both epigenetic regulatory enzymes and epigenetic reg-
ulatory complexes46–48 suggests a prominent emerging
new role for these compounds and other recently char-
acterized CtBP inhibitors21,22 in combinatorial strategies
for epigenetic intervention. Although these compounds
bind with modest affinity (in the micromolar range), they
serve as prototypes from which to bootstrap the design of
novel molecules with higher binding affinity and activity
toward CtBP-regulated pathways. Similarly, although
pargyline shows measurable synergy with CtBP inhibitors,
its primary use in clinical trials has been associated with
treatments for hypertension. Nonetheless, there is
renewed interest in therapeutic targeting of LSD1 as
several new compounds that disrupt LSD1 function
including: GSK2879552, ORY-100, 4SC-202, IMG-7289,
INCB-59872, and tranylcypromine derivatives, are being
assessed in clinical trials for activity against leukemia43.
This is particularly relevant given the recent finding that
loss of LSD1 is associated with an enhanced anti-tumor
response through upregulation of double-stranded RNA
stress response secondary to lost repression of endogen-
ous retroviral elements49. Furthermore, analysis of TCGA
data show an inverse relationship between CD8+ T-cell
infiltration and the RNA levels of LSD149. It is not clear
what underlies the cell-type specific dose sensitivity we
have observed in the current study, however, this has been
observed with other CtBP inhibitors10. Whether or not it
reflects sensitivity thresholds based on the level of epi-
thelial differentiation in breast cancer will require exten-
sive investigation beyond the scope of this initial proof-of-
principle report. Such issues may become better resolved
with the development of 2nd or 3rd generation CtBP
inhibitors that act with higher affinity. Currently, the most
potent compound appears to be CI24 which shows the
highest uniform correlation in potency of transcriptional
de-repression, with eviction of chromatin modifiers,
influences on cell migration/invasion, and increase in
DNA repair. The provocative finding that differential
enrichment of CtBP1/LSD1 shows selective influence on
ERRB2/4 signaling (Fig. 8c) suggests a broader application
of this targeting strategy beyond TNBC subtypes. More-
over, it suggests additional opportunities for combined
therapy. An important aspect of this current study is the
correlation of nuclear levels of CtBP1 and LSD1 with gene
expression patterns in patient samples. Although cell lines
are an easily tractable system that led to the cell-type
specific identification of GATA3, FOXA1, and OVOL2 as
major regulatory targets of CtBP, these genes do not show
up as top targets in patient samples (Fig. 8). This reflects
the innate heterogeneity and plasticity of patient breast
cancer tissues and also is consistent with the significant
cell type-specificity of the influence of CtBP inhibition,
mentioned previously (Fig. 4), and observed in CtBP-
depleted cell lines14. Other notable correlations found in
patient samples is the high significance of the DNA repair
genes ATM, LIG4, PARP3, SETX, and GRF2H4 genes
revealed by ANOVA analysis of the CtBP1/CTBP2 high
category (see Supplementary Table 1). In summary, the
findings in this study provide a new and novel conceptual
groundwork for the development of more effective
treatment strategies and introduce a novel class of com-
pounds to be explored in combinatorial strategies to
exploit vulnerabilities in the epigenetic regulation of
breast cancer.
Materials and methods
Cell lines and constructs
MDA-MB-231 and MCF-7 cells were purchased from
ATCC. All starting cultures were screened for myco-
plasma contamination approximately 4–5 months prior to
use, and experiments were conducted on cell lines grown
for no more than 13–15 passages. Short hairpin sequences
for RNAi depletion of CtBP1 and CtBP2 were cloned into
the doxycycline-inducible (Tet-ON) pINDUCER lentiviral
vector system that produces a miR30-based short hairpin
that targets both CtBP1 and CtBP213,50. CFP-CTBP1
and YFP-CTBP2 plasmids were provided by Dr. Jermey P.
Blaydes51.
Cell culture and tissues
MDA-MB-231 and MCF-7 cells were maintained in
regular DMEM supplemented with 10% (v/v) FBS,
penicillin-streptomycin (Invitrogen) and insulin as pre-
viously described14.
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Computer-assisted drug design
ChemNavigator iResearch Library from Sigma Aldrich24
was searched for molecules containing oxaldehydic acid
structures similar to MTOB or structurally similar pro-
panedioic, 3-oxobutanoic, and 4-oxopropanoic acid.
These moieties can form favorable interactions with three
residues (His315, Glu295, Arg 266) demonstrated to
function as a catalytic triad in the active site of CtBP in
addition to other essential residues at the catalytic site,
including Arg266 and Arg678. Quantitative structure-
activity relationship (QSAR) models were generated using
MTOB and a series of 11 alpha-keto acids with measured
kinetic properties for the catalytic domain of CtBP. The
best model obtained was then applied against the set of
selected acidic compounds from ChemNavigator, and
compounds with high predicted substrate activity values
were filtered for drug-like properties using the Lipinski
Rule52. Filtered candidates selected by the QSAR model-
ing were then further evaluated by docking into the
published crystallographic structure of the CtBP dehy-
drogenase core with NAD+ and acetic acid8. Docking was
done using Glide (27) and the docked compound struc-
tures were required to be stabilized by at least two
hydrogen bonds to Arg266, Gly101 or His315 in the CtBP
active site. This screen identified 31 compounds of which
24 were commercially available. (See virtual screening
methods in Supplementary materials and methods)
Acceptor photobleaching FRET
Expression vectors for CFP-CtBP1 (pSCFP3A) and YFP-
CtBP2 (pSYFP2) were co-transfected into MDA-MB-231
wild-type cells using lipofectamine 2000 reagent (Thermo
Fischer Scientific). 2 × 104 cells/well were seeded into
Nunc Lab-Tek 8 chambered coverglass (Thermo Fischer
Scientific). Cells were then treated with either 100 μM of
Tris control vehicle or 10 μM of the four different CtBP
Inhibitors (CI19, CI22, CI23, and CI24). We used a
plasmid encoding a CFP-YFP fusion protein with a 2-aa
spacer between CFP and YFP as a positive control for
FRET29. Co-transfection with CFP-CtBP1 (pSCFP3A) and
unconjugated YFP (pCMV6AC-mYFP) plasmids were
used as negative control. Cells were imaged with a 60 × 1.4
NA Zeiss immersion objective and ×2 zoom using 514 nm
laser line of argon laser (25 mW) and 405 nm laser line of
Diode laser (30 mW) on LSM780 confocal microscope
(Carl Zeiss, Inc, Thornwood, NY, USA) in the Optical
Microscopy Core (NCI/CCR/LRBGE). YFP was photo-
bleached by scanning the whole cell 10 times using the
514 laser line of an argon laser at 100% intensity. The
efficiency of Fluorescence Resonance Energy Transfer
(FRET) EF was measured by acceptor photobleaching
method as described29 based on the equation: EF=
(ICFP, after − ICFP, before)/ICFP, after, where ICFP, after and ICFP,
before referring to CFP intensities after and before YFP
photobleaching, respectively. Each sample was scored for
greater than 15 nuclei in order to achieve statistical sig-
nificance. 15 regions of interest were randomly measured
within each nucleus. A FRET signal was considered be
positive if the FRET efficiency values (EF) obtained in the
experiment exceeded those of random FRET in the
negative control.
Chromatin immunoprecipitation and immunoprecipitation
ChIP was performed as previously described53 and the
list of primers and antibodies used in the study are pro-
vided in the Supplementary materials and methods.
Western blotting RNA isolation, and RT-qPCR
RNA isolation from cell lysates and RT-qPCR were
performed as described previously53 and normalized to
18S rRNA. The total RNA was prepared using the
RNAeasy kit (Qiagen) following the manufacturer’s pro-
tocol. The RNA was quantified and 1 μg of total RNA was
used for each reverse transcription. Reverse transcription
was carried out by following the QuantiTect® Reverse
Transcription procedure (Qiagen). For western blotting,
the cells were collected and resuspended in RIPA lysis
buffer (50 mM Tris pH 7.5, 1 mM EDTA, 150 mM NaCl,
0.1% SDS, 1% TritonX-100, 1% sodium deoxycholate and
freshly added proteinase inhibitor cocktail) for 30 min on
ice. The lysates were centrifuged for 20 min at 12,000 rpm
and the supernatants were used for quantitation and
western blotting. Nuclear extracts were prepared and
analyzed as described previously53.
Invasion and migration assays
Invasion assay was performed using MDA-MB-231 cells
with the Corning® Biocoat™ Matrigel® Invasion Chambers
(cat. 354480). Replicates were carried out according to the
manufacturer’s recommendation after 24 h of treatment
of Tris and 10 μM CtBP inhibitors (CI19, CI22, CI23, and
CI24). After 24 h of the invasion, the membranes were
washed in 1X PBS, fixated in methanol, stained with
DAPI, and visualized. Wound closure assay was per-
formed using the Radius™ assay from Cell Biolabs, Inc.
Cells were incubated 24 h with 10 μM CtBP inhibitors
prior to initiation of the migration assay. For assays
comparing cellular migration in response to combined
addition of drugs, cellular migration was measured using
the IncuCyte® ZOOM System, real-time, a quantitative
live-cell analysis system for high definition phase contrast
images to monitor wound closer over time as directed by
the manufacturer’s instructions.
Gamma H2A.X foci formation assay
MDA-MB-231 wild type and CtBP1/2 knockdown cells
were seeded in 8 chamber slides at a density of
10,000 cells/well. MDA-MB-231 wild type cells were
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treated with the CtBP inhibitors (CI19, CI22, CI23, and
CI24) and Tris Control for 24 h prior to Gamma Irra-
diation. MDA-MB-231 wild type and CtBP1/2 knock-
down cells were exposed to 5 Gy of Gamma irradiation.
After 0, 12, and 24 h post-Gamma irradiation, cells were
washed three times with 1× PBS, fixed with 3.5% paraf-
ormaldehyde for 20 min followed by 70% cold ethanol
overnight. Cells were then washed three times with 1×
PBS, stained with anti-phospho-Histone H2A.X antibody
(Ser139) (catalog # 05-636, Millipore) at 1/1000 primary
antibody dilution for 1 h, washed three times with 1×
PBS, followed by staining with secondary Alexa Fluor 488
goat anti-mouse antibody (Catalog # A11001, Life
Technologies) at 1/2000 dilution for one hour. Cells were
then washed three times with 1× PBS followed by stain-
ing with 1/5000 DAPI dilution. Cells were then mounted
with anti-fade mounting media and covered with cover-
slips. Different fluorescent images were taken with
Axiovert 200M and only cells with 3 plus phospho-H2A
foci were scored.
Methods for immunohistochemistry
Tissue microarray construction and scoring
Following IRB approval from East Carolina University
and the National Institutes of Health Intramural research
program, approximately 180 de-identified formalin-fixed
and paraffin-embedded tissue from patients who were
diagnosed and underwent surgery for Stage 0 to Stage IV
breast cancer between 2001 and 2010 at Pitt County
Memorial Hospital (now Vidant Medical Center),
Greenville, NC. Following a review of hematoxylin and
eosin-stained sections, regions of interest were outlined,
and 1mm cores were removed from corresponding blocks
using a Pathology Devices TMArrayer (Westminster,
MD). All arrays contained appropriately chosen positive
and negative control tissue. Digital image analysis and
scoring of IHC staining was performed using Leica Aperio
digital analysis platforms, in which three representative
regions of tumor were outlined on each core by a
pathologist and scored digitally using the Nuclear v9
algorithm (CtBP1, CtBP2, and LSD1) to generate a histo-
score (H-Score; 0–300) based on the percent of positive
cells with assigned intensity thresholds of negative (0), low
(1), moderate (2) or high (3) as previously described54.
Breast tumor tissue microarrays were stained, using
monoclonal primary antibodies, CTBP1 and CTBP2
(33871, 39008 Millipore) at 1:100,000 overnight with high
pH (Catalog No. M361201-2, DAKO). LSD1 (Abcam,
ab129195) staining was done at 1:2000 overnight with low
pH (Catalog No. MA5-13191, DAKO). Using the assigned
scale of 1–300, patients were then classified into terciles
based on the H-Scores for CtBP1, CtBP2, and LSD1,
respectively. The data was then categorized into terciles
based on the divided ordered distribution into three parts,
each containing a third, i.e. 33.33% of a given population.
The first tercile (low) represents the lowest 33.33% of the
data (1–33.33%); the second tercile represents the med-
ium 33.33% value (33.34–66.66%) and third highest 33.33
value (66.34–100%). Based on those protein values, the
patients were classified into these three categories and
defined them as low, medium and high. Finally, patients
were segregated into combined CtBP1: LSD1 categories of
Low: Low; Medium: Medium; and High: High and used
for comparison of their gene expression patterns.
RNA-seq
Following a review of H&E stained slides areas of tumor
with >80% nuclei were circled, and 2.5 × 2–3mm tissue
cores were extracted from the corresponding regions of
FFPE tissue blocks for N= 126 patients. Sample cores were
shipped to BGI Beijing Genome Institute (BGI) for further
processing as previously described55,56. Briefly, the total
RNA samples were first treated with DNase I, followed by
an mRNA enrichment step enriched by using the oligo
(dT) coupled magnetic beads. Following fragmentation, the
first strand of cDNA was synthesized by using random
hexamer-primers. Buffer, dNTPs, RNase H and DNA
polymerase I were added to synthesize the second strand.
The double-strand cDNA was purified with magnetic
beads and end reparation and 3’-end single nucleotide A
(adenine) addition was then performed. Finally, sequencing
adaptors were ligated to the fragments. The fragments
were enriched by PCR amplification. During the QC step,
Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time
PCR System were used to qualify and quantify the sample
library. The library was sequenced (60M paired-end read
per sample) on an Illumina HiSeqTM4000.
Sequence data analysis
After sequencing, the raw reads were filtered (BGI).
Data filtering included removing adapter sequences,
contamination and low-quality read from raw reads. The
cleaned reads (fastQ) were mapped to the reference
sequence using HISAT57. Raw reads and RPKM for each
sample were calculated using HOMER58. Differential gene
expression was performed using EdgeR59.
Statistical analysis
A Spearman rank correlation test was performed to test
the relation between its protein H-score and gene
expression (RPKM value) values60. A completely unsu-
pervised hierarchical clustering approach was performed
on all 486 breast samples of the protein data set.
Complete linkage and distance correlations were used
for clustering protein data with bootstrap resampling
techniques. The stability of the clustering was estimated
with the ‘pvclust’ R package61 available on CRAN
http://cran.rproject.org/web/packages/ pvclust/). A two-
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sided t-test was employed to test the null hypothesis (H0)
assumption of equality of the protein values in two
defined groups of data and demonstrated by violin plots
using R software and ggplot2 package62. ANOVA and
logistic regression analysis were conducted using R sta-
tistical analysis software. A p-value thresholds 0.05 was
applied to select the top significant genes (Supplementary
Table 1). A reactome open-source browser (version 3.6),
with curated and peer-reviewed pathway database (reac-
tome release 67) was used for pathway analysis of the top
genes identified (https://reactome.org/PathwayBrowser/).
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